BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Pier 88 Health and Theranica Secure NMPA Approval for Nerivio® REN Wearable in China

Pier 88 Health, a digital health company dedicated to reshaping chronic pain management and bringing breakthrough global medical innovations to Greate...

September 30, 2025 | News

WuXi Biologics Launches TrueSite TI™, a Next-Generation Targeted Integration Cell Line Platform Redefining Biologics Development

TrueSite TI™, the fourth generation of WuXia™ cell line platform, leverages targeted integration technique to streamline clone scre...

September 29, 2025 | News

Hengrui Pharma Grants Glenmark Exclusive Global Licence for HER2-Targeted ADC Trastuzumab Rezetecan

Hengrui Pharma, a leading innovative global pharmaceutical company focused on scientific and technological innovation, announced that it has entered ...

September 25, 2025 | News

China’s NMPA Approves Innovent’s Mazdutide, the World’s First Dual GCG/GLP-1 Receptor Agonist for Type 2 Diabetes

Innovent Biologics, Inc. a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatm...

September 22, 2025 | News

Kexing Biopharm Completes FDA Type II DMF Registration for Stem Cell-Derived Exosomes

Kexing Biopharm announced that its investigational Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes has successfully completed a Type II Drug Ma...

September 18, 2025 | News

WuXi Biologics Secures First Turkish GMP Certification for Three Facilities

WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that three of its manufacturin...

September 18, 2025 | News

EC Approves Alteogen’s EYLUXVI® as Eylea® Biosimilar for Major Ophthalmic Indications

EYLUXVI® is the second biosimilar approved for Alteogen following the launch of the Herceptin® biosimilar in China through it...

September 18, 2025 | News

Mabwell and Aditum Bio Launch Kalexo Bio with $1 Billion siRNA Deal for Dyslipidemia and ASCVD

Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH) and Aditum Bio announced the launch of Kalexo Bio, a new company formed in conjunction with an exc...

September 18, 2025 | News

US, China and Australia Begin Phase 2 Trial of Atom Therapeutics’ ABP-745 for Acute Gout Flares

ABP-745 is an oral small molecule drug with potential applications, for other inflammatory conditions such as cardiovascular disease Atom T...

September 17, 2025 | News

China’s Biocytogen Licenses Fully Human Antibody to Tubulis for Novel ADC Development

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel ...

September 17, 2025 | News

Phrontline Biopharma Doses First Patient in Phase 1 Trial of TJ101, an EGFR/B7-H3 Antibody–Drug Conjugate

Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the first ...

September 16, 2025 | News

Rona Therapeutics Submits RN3161 to Australian HREC as INHBE-Targeting GalNAc siRNA for Obesity

Rona Therapeutics, a global leader in developing next-generation RNAi therapeutics, announced the successful submission of RN3161 to the Australian Human R...

September 16, 2025 | News

BioAge Advances BGE-102 into Phase 1 Trials Triggering Milestone Payment to HitGen as DEL Technology Accelerates Drug Discovery

BGE-102, an orally available, brain-penetrant NLRP3 inhibitor, was developed from a hit compound identified using HitGen's industry-leading DEL technolog...

September 16, 2025 | News

Alphamab Oncology’s NDA for KN026 Accepted by NMPA for HER2-Positive Gastric Cancer

Alphamab Oncology announced that the New Drug Application (NDA) for anbenitamab injection (KN026), independently developed by the Company and co-developed ...

September 15, 2025 | News

Stay Connected